BBBaroda BNP ParibasRegular · Growth

Baroda BNP Paribas Health and Wellness Fund - Regular Plan - Growth

Pharma & Health CareEquity - Sectoral Fund - Pharma & Health CareBenchmark: BSE Health Care - TRI
NAV · 16 Sep 2026₹10.57-0.14%
AUM₹507 Cr
Expense Ratio2.79%
1Y CAGR+8.31%
Exit LoadNIL upto 10% of units and 1% for remaining units on or before 1Y, Nil after 1Y
Min SIP₹500
Launched2025

Investment Objective

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.

Fund Mandate

Equity and equity related instruments of companies in the Pharma & Healthcare and allied sectors80%–100%
Equity and equity related instruments of companies other than above0%–20%
Money Market and other liquid instruments , Gold and Silver instruments (through ETFs)0%–20%
Units issued by InvITs0%–10%
Units of Mutual Funds as permitted by SEBI0%–10%
Asset Allocation
Domestic Equity98.8%
Cash & Equivalents1.2%
Fund Managers
SC
Sanjay Chawla
Fund Manager
Key Information
2.79%
₹500
₹1,000
NIL upto 10% of units and 1% for remaining units on or before 1Y, Nil after 1Y
Nil
Inception27 Jun 2025
AMCBaroda BNP Paribas
Top Holdings
1Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology9.01%
2Divi's Laboratories LimitedPharmaceuticals & Biotechnology8.01%
3Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology7.99%
4IPCA Laboratories LimitedPharmaceuticals & Biotechnology6.23%
5Lupin LimitedPharmaceuticals & Biotechnology5.99%
6Laurus Labs LimitedPharmaceuticals & Biotechnology5.66%
7Apollo Hospitals Enterprise LimitedHealthcare Services5.44%
8Fortis Healthcare LimitedHealthcare Services4.50%
9AstraZeneca Pharma India LimitedPharmaceuticals & Biotechnology3.56%
10Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology3.42%
Sector Allocation
Pharmaceuticals & Biotechnology67.2%
Healthcare Services15.4%
Insurance2.4%
Trailing Returns
PeriodReturnsCategory avg
1 Day-0.14%
1 Week-2.00%-2.62%
1 Month-0.97%-4.01%
3 Months+6.18%+0.58%
6 Months+13.73%+9.14%
9 Months+12.17%+1.98%
1 Year+8.31%+1.64%
+4.79%+16.23%

Category avg is the average return of every scheme in this fund's SEBI class (Equity - Sectoral Fund - Pharma & Health Care) over the same period. Returns up to 1 year are absolute; returns beyond 1 year are annualised (CAGR). This is Accord's own stated convention for equity-oriented schemes.

Risk Metrics
9.66%

A measure of how much a fund's returns swing up and down over time. Higher means a bumpier ride — more volatility — even if the average return ends up the same as a steadier fund.

0.39

How sensitive a fund is to overall market moves. A beta of 1 means it roughly moves in line with the market; below 1 means smaller swings than the market; above 1 means bigger swings in both directions.

-1.44

How much extra return a fund earned for every unit of risk (volatility) it took on, compared to a safe, risk-free investment. Higher means better risk-adjusted performance — not just higher returns, but smarter ones.

-9.76%

The extra return a fund generated above what its benchmark index would predict, given the risk it took. Positive alpha suggests the fund manager added genuine value beyond just tracking the market.

-2.69

Similar to the Sharpe Ratio, but only counts downside volatility (the bad kind) rather than penalizing a fund for volatile-but-positive swings. Higher means better returns per unit of "harmful" risk.

-6.23%

The single worst peak-to-trough fall a fund has experienced over a given period — the deepest "how much would I have lost if I'd bought at the top and sold at the bottom" scenario.

Fees
2.79%
NIL upto 10% of units and 1% for remaining units on or before 1Y, Nil after 1Y
Nil
₹500
₹1,000
Capital Gains Tax, general rules

This is an equity-oriented fund. Under rules effective since Budget 2024 (23 July 2024):

Short-Term Capital Gains (held ≤ 12 months): taxed at a flat 20%.

Long-Term Capital Gains (held > 12 months): taxed at 12.5% on gains above ₹1.25 lakh in a financial year, with no indexation benefit.

General information only, not tax advice, actual liability depends on your overall income and applicable law at the time of redemption. Consult a tax advisor for your specific situation.

Frequently Asked QuestionsGeneral mutual-fund FAQs, not specific to this scheme